Andrew J. Muir, MD, MHS
Clinical Director, Hepatology
Department / Division
Medicine /
Medicine - Gastroenterology
Address
DUMC 3913
Durham, NC 27710
Appointment Telephone
919-684-6437
Office Telephone
919-684-2052
Fax Telephone
919-684-8264
- MD, Duke University School of Medicine, 1993
- Internal Medicine, Duke University Medical Center, 1993-1996 (Chief Resident, 1997-1998)
- Gastroenterology, Duke University Medical Center, 1996-1997, 1998-2000
Clinical Interests
General hepatology, transplant hepatology, hepatitis C, hepatocellular carcinoma
Research Interests
· Hepatitis C
· Liver Transplantation
· Hepatocellular carcinoma
· Clinical Trials
· Racial disparities in liver disease
· Outcomes Research
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Abbott Laboratories
- Achillion Pharmaceuticals
- Bristol-Myers Squibb
- Cook Medical
- Gilead Sciences, Inc.
- GlaxoSmithKline
- GlobeImmune, Inc.
- Janssen Pharmaceuticals (Johnson & Johnson)
- Merck
- Novartis
- Pfizer Inc.
- Profectus
- Roche
- Salix Pharmaceuticals, Ltd.
- Vertex Pharmaceuticals Inc.
Representative Publications
Muir, AJ. The protease inhibitor era: an opportunity to improve the quality of care. Digestive Diseases and Sciences. 2011;56:1252-1254.
(2011)
Abstract
Muir, AJ; Hu, KQ; Gordon, SC; Koury, K; Boparai, N; Noviello, S; Albrecht, JK; Sulkowski, MS; McCone, J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. Journal of Viral Hepatitis. 2011;18:e134-e143.
(2011)
Abstract
Muir, AJ; Poordad, FF; McHutchison, JG; Shiffman, ML; Berg, T; Ferenci, P; Heathcote, EJ; Pawlotsky, JM; Zeuzem, S; Reesink, HW; Dusheiko, G; Martin, EC; George, S; Kauffman, RS; Adda, N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54:1538-1546.
(2011)
Abstract
Jou, JH; Chen, PH; Jazwinski, A; Bouneva, I; Smith, AD; Muir, AJ. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Digestive Diseases and Sciences. 2010;55:3591-3596.
(2010)
Abstract
McHutchison, JG; Manns, MP; Muir, AJ; Terrault, NA; Jacobson, IM; Afdhal, NH; Heathcote, EJ; Zeuzem, S; Reesink, HW; Garg, J; Bsharat, M; George, S; Kauffman, RS; Adda, N; Di Bisceglie, AM; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. New England Journal of Medicine. 2010;362:1292-1303.
(2010)
Abstract
Muir, AJ; Shiffman, ML; Zaman, A; Yoffe, B; de la Torre, A; Flamm, S; Gordon, SC; Marotta, P; Vierling, JM; Lopez-Talavera, JC; Byrnes-Blake, K; Fontana, D; Freeman, J; Gray, T; Hausman, D; Hunder, NN; Lawitz, E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822-832.
(2010)
Abstract
Ge, D; Fellay, J; Thompson, AJ; Simon, JS; Shianna, KV; Urban, TJ; Heinzen, EL; Qiu, P; Bertelsen, AH; Muir, AJ; Sulkowski, M; McHutchison, JG; Goldstein, DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
(2009)
Abstract
McHutchison, JG; Everson, GT; Gordon, SC; Jacobson, IM; Sulkowski, M; Kauffman, R; McNair, L; Alam, J; Muir, AJ; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine. 2009;360:1827-1838.
(2009)
Abstract
McHutchison, JG; Lawitz, EJ; Shiffman, ML; Muir, AJ; Galler, GW; McCone, J; Nyberg, LM; Lee, WM; Ghalib, RH; Schiff, ER; Galati, JS; Bacon, BR; Davis, MN; Mukhopadhyay, P; Koury, K; Noviello, S; Pedicone, LD; Brass, CA; Albrecht, JK; Sulkowski, MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine. 2009;361:580-593.
(2009)
Abstract
Brady, CW; Smith, AD; Stechuchak, KM; Coffman, CJ; Tuttle-Newhall, JE; Provenzale, D; Muir, AJ. Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. Liver Transplantation. 2008;14:228-234.
(2008)
Abstract
Jou, JH; Muir, AJ. In the clinic. Hepatitis C. Annals of Internal Medicine. 2008;148:ITC6-1-ITC6-16.
(2008)
Abstract
Lawitz, E; Rodriguez-Torres, M; Muir, AJ; Kieffer, TL; McNair, L; Khunvichai, A; McHutchison, JG. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. Journal of Hepatology. 2008;49:163-169.
(2008)
Abstract
Patel, K; Muir, AJ; McHutchison, JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006;332:1013-1017.
(2006)
Abstract
Ramamurthy, M; Muir, AJ. Treatment of hepatitis C in special populations. Clinics in Liver Disease. 2006;10:851-865.
(2006)
Abstract
Condron, SL; Heneghan, MA; Patel, K; Dev, A; McHutchison, JG; Muir, AJ. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation. 2005;80:145-148.
(2005)
Abstract
Muir, AJ; Bornstein, JD; Killenberg, PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine. 2004;350:2265-2271.
(2004)
Abstract
